At Avalere Health, we are cementing our commitment to patients with chronic inflammatory skin conditions by welcoming FIDE to our group.

FIDE is an independent, expert-led consultancy specializing in dermatology and offering direct and unrivaled access to independent insights from a network of leading dermatologists. The organization gives biopharmaceutical companies an unfiltered view of the market landscape, providing unique insights into the critical issues for patient care—from early phase research to real-world evidence post-approval.

FIDE’s experts comprise of the top key opinion leaders across the globe.

• Bruce E Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine and Central Connecticut Dermatology in Cromwell, CT
• Kenneth B Gordon, MD, Professor and Chair of Dermatology at the Medical College of Wisconsin
• Richard GB Langley, MD, Director, Professor and Director of Research in the Division of Dermatology, Dalhousie University
• Richard Warren, MD, Professor and Director of the Dermatopharmacology Unit at the University of Manchester in the UK

Skin diseases are the fourth most common of all human diseases and affect more than one-third of the world’s population. However, the psychological and physical impact of these conditions is often vastly underestimated. Studies have shown that chronic inflammatory skin diseases significantly affect patients’ quality of life, often leading to comorbidities, including mental health conditions such as depression and anxiety.

Biopharmaceutical companies are increasingly focusing their attention on developing treatments for these chronic dermatological conditions, with more than 80 products in development to treat atopic dermatitis and psoriasis. This increase in research and development has created a crowded market and an abundance of data that healthcare professionals often find challenging to navigate. With FIDE’s specialists, we can better equip our dermatology clients with the knowledge and skills necessary to meet their stakeholders’ complex and evolving needs.

Bruce Strober, MD, PhD, Executive Director at FIDE, explained: “There is a fantastic opportunity for life science companies to better support dermatologists in navigating the innovations launching in the next few years. By joining Avalere Health, we can connect our knowledge of the field with Avalere Health’s deep expertise in services supporting clients through the product lifecycle to help life science companies transform patients’ lives.”

Armed with FIDE’s insights and expertise, life science companies can better understand the critical issues for improving health outcomes for patients across the globe while also achieving business success. Our clients operating in dermatology will benefit from a suite of services spanning medical communications; marketing; value, evidence, and access; and strategy, underpinned by insights and advice from the world’s leading experts in the field.

“FIDE is a compelling addition to our group,” said Group President Gail Flockhart. “The company’s expert-led approach provides our clients with insights into a highly innovative and complex market with significant unmet patient needs. We have worked with FIDE for more than a decade, and our partnership has been tremendously successful in supporting clients with access to expert insight. We are delighted to continue to deliver this work and to develop the service offering further now they are fully part of the group.”

Jon Koch, Avalere Health CEO, added: “I’m incredibly excited to welcome such a talented team to our organization. FIDE’s key opinion leaders will add a unique lens to our services for our dermatology clients—one that I have not seen before in the agency and consulting worlds. When combined with our team’s expertise across the product life cycle, we can solve an array of complex challenges for our clients, empowering them with novel solutions that truly get to the heart of healthcare professionals’ and patients’ challenges.”

This article was originally published on November 11, 2021.